Get the Stockscreener App
6.5605
9.14%
-0.8895
Turn Therapeutics Inc stock is traded at $6.5605, with a volume of 104.36K.
It is down -9.14% in the last 24 hours and up +0.00% over the past month.
Turn Therapeutics Inc is a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble APIs in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis.
See More
Previous Close:
$7.45
Open:
$7.19
24h Volume:
104.36K
Relative Volume:
0.34
Market Cap:
$208.77M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.7007
$7.19
1-Week Range:
$6.75
$26.50
52-Week Range:
$6.75
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Compare TTRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
6.73 | 208.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.19 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.50 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
797.00 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Turn Therapeutics Inc Stock (TTRX) Latest News
Turn Therapeutics files prospectus relates to offer, sale of up to 7 mln shares - MarketScreener
Stock skyrockets after Turn goes public - BioWorld MedTech
Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings - Benzinga
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype? - ts2.tech
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? - Yahoo Finance
US Stocks Mixed; Nasdaq Falls Over 50 Points - inkl
Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews
Stock Market Today: S&P 500, Nasdaq Futures Slip As Fed Minutes Signal Tariff-Related Uncertainty—PepsiCo, Delta, Levi Strauss In Focus (UPDATED) - Benzinga
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today? - MSN
Turn Therapeutics Shares Skyrocket 134% After Hours Following Nasdaq Debut - Benzinga
After-Hours Surge: Turn Therapeutics Rockets 134% Post-Close On Nasdaq Debut; Biotech Stocks Rally - Nasdaq
Turn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Turn Therapeutics to Commence Trading Today on Nasdaq - Yahoo Finance
Turn Therapeutics (Direct Listing) Plans $0.00 IPO for Week of October 13th (TTRX) - Defense World
Turn Therapeutics Inc. Announces Board and Committee Appointments, Effective September 30, 2025 - MarketScreener
Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout - PR Newswire
Turn Therapeutics Announces Expected First Day of Trading on NASDAQ Global Market - Business Wire
Can Zevra Therapeutics (ZVRA) Turn Clinical Momentum Into Sustainable Competitive Advantage? - Yahoo Finance
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics to Host Open Investor Session in Connection with Expected Public Listing on Nasdaq - Business Wire
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? - Yahoo Finance
After dropping IPO plans, Odyssey Therapeutics turns to VC for capital - The Business Journals
TTRX IPO NewsWound and dermatology-focused Turn Therapeutics files for a direct listing on the Nasdaq - renaissancecapital.com
Superbug Survivor and Turn Therapeutics CEO Launches Podcast to Spotlight Hidden Scientific Breakthroughs - Business Wire
Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P - The Economic Times
Turn Therapeutics Begins Clinical Trial of First Topical IL-36/IL-31 Inhibitor for Eczema - Business Wire
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday - Benzinga
InMed Pharmaceuticals’ Surprising Stock Rise: A Profitable Turn? - timothysykes.com
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Turn A Profit? - simplywall.st
China is catching up to the U.S. in pharmaceuticals, but it’s not too late to turn that around - Fast Company
Vertical Aerospace Ltd. (NYSE:EVTL) Is About To Turn The Corner - Yahoo Finance
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga
Turn Therapeutics Announces Vaccine Breakthrough: Validates 100% VSV Recovery from Petrolatum Carrier at 24 and 72 Hours - Business Wire
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - Yahoo Finance
Spevigo so-so, innovator takes another Turn at IL-36 in eczema - BioWorld MedTech
When Will Rakovina Therapeutics Inc. (CVE:RKV) Turn A Profit? - Yahoo Finance
Turn Therapeutics Launches Final Crowdfund Round Ahead of Eczema Trial Enrollment, Engages Clear Street to Explore Public Markets - Yahoo Finance
Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for Its Epigenetic Reprogramming Therapies - PR Newswire
Cell therapy biotech Century Therapeutics axes cancer trial, turns to autoimmune - Fierce Biotech
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - Yahoo Finance
Biotech startup looks to turn founders' experience, $20 million against epilepsy - The Business Journals
Can Contineum's Upcoming Catalysts Turn The Tide In The Coming Months? - RTTNews
TransCode Therapeutics: A Turning Point for RNAZ? - StocksToTrade
You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers - BioSpace
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
Viking Therapeutics: The Turning Point Is Not Here Yet - Seeking Alpha
Stock market today: Dow pops, Nasdaq slips as focus turns to CPI inflation report - Yahoo Finance
Turn Therapeutics Secures $75 Million Investment Commitment Tied to Public Listing - Yahoo Finance
Turn Therapeutics Inc Stock (TTRX) Financials Data
There is no financial data for Turn Therapeutics Inc (TTRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.81%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):